多基因风险评分与单相抑郁锂增疗效的关联
该队列研究纳入193例抗抑郁药应答不足的单相抑郁患者,分析精神分裂症、重性抑郁和双相障碍多基因风险评分与锂增疗效的关联。双相障碍多基因风险评分较高与应答和缓解均相关,重性抑郁多基因风险评分较低与更好应答相关,精神分裂症多基因风险评分无显著关联。
要点
- 双相障碍多基因风险评分最高三分位者应答可能性为最低三分位的2.02倍。
- 重性抑郁多基因风险评分较低与锂增应答较好相关(HR 0.81)。
- 精神分裂症多基因风险评分与锂增应答或缓解均无显著关联。
核心结论
- 双相障碍多基因负荷较高和重性抑郁多基因风险较低的患者更可能从锂增中获益。
研究设计与样本
- 队列研究分析2008至2020年来自13家精神病院、抗抑郁药应答不足且HAMD-17≥12的单相抑郁患者锂增治疗结局。
- 使用全基因组关联研究汇总统计量计算疾病特异性多基因风险评分。
主要发现
- 在193例患者中,双相障碍多基因风险评分较高与应答(HR 1.29;95%CI 1.02-1.63;P=.03)和缓解(HR 1.52;95%CI 1.14-2.04;P=.004)相关。
- 双相障碍多基因风险评分分别解释应答和缓解变异的2.51%和4.53%。
- 双相障碍多基因风险评分最高三分位者应答可能性为最低三分位的2.02倍(95%CI 1.15-3.53),缓解可能性为2.26倍(95%CI 1.17-4.36)。
- 重性抑郁多基因风险评分较低与更好应答相关(HR 0.81;95%CI 0.66-1.00;P=.048;Nagelkerke R2=1.99%)。
- 精神分裂症多基因风险评分与应答(HR 1.00;95%CI 0.80-1.24;P=.97)或缓解(HR 1.12;95%CI 0.85-1.48;P=.42)无显著关联。
关键数值与推荐
- 应答定义为HAMD-17评分降低≥50%,缓解定义为HAMD-17评分≤7。
- 采用Cox比例风险模型,校正祖源、人口学和临床协变量,估计有利结局的风险比。
临床怎么用
- 疾病相关多基因风险评分可能辅助构建锂增应答预测模型,为临床决策提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Lithium augmentation is an effective treatment for patients with major depression after inadequate antidepressant response, but therapeutic outcomes vary considerably between individuals. Molecular studies may provide novel insights into treatment prediction and guide personalized therapy. OBJECTIVE: To investigate the association of polygenic risk scores (PRS) for schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BIP) with clinical outcomes after lithium augmentation. DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed prospectively assessed treatment outcomes in patients who underwent lithium augmentation. Disorder-specific PRS were calculated using well-powered genome-wide association study summary statistics. Participants were recruited from 13 psychiatric hospitals, primarily in the greater Berlin area, between 2008 and 2020. They were patients with MDD who showed inadequate response to at least 1 antidepressant, a baseline score of 12 or more on the 17-item Hamilton Depression Rating Scale (HAMD-17), adequate treatment duration (≥4 weeks), and no diagnostic or co-medication changes. Data analysis was conducted between June 2022 and November 2023. EXPOSURE: Polygenic risk scores for MDD, SCZ, or BIP. MAIN OUTCOMES AND MEASURES: Response was defined as a 50% or greater reduction in HAMD-17 score, remission as a HAMD-17 score of 7 or less. Cox proportional hazards models, adjusted for ancestry, demographic, and clinical covariates, were used to estimate hazard ratios (HRs) for favorable outcomes. RESULTS: Among 193 patients (mean [SD] age, 49.5 [13.4] years; 118 [61.1%] female and 75 [38.9%] male), higher BIP-PRS were associated with both response (HR, 1.29; 95% CI, 1.02-1.63; P = .03) and remission (HR, 1.52; 95% CI, 1.14-2.04; P = .004), explaining 2.51% and 4.53% of the variability in treatment outcomes, respectively. Individuals in the highest tertile of the BIP-PRS distribution had a 2.02-fold (95% CI, 1.15-3.53) higher likelihood of response and a 2.26-fold (95% CI, 1.17-4.36) higher chance of remission compared with those in the lowest tertile. Additionally, lower MDD-PRS was associated with better response to lithium augmentation (HR, 0.81; 95% CI, 0.66-1.00; P = .048; Nagelkerke R2 = 1.99%). No significant associations were observed between SCZ-PRS and response (HR, 1.00; 95% CI, 0.80-1.24; P = .97) or remission (HR, 1.12; 95% CI, 0.85-1.48; P = .42). CONCLUSIONS AND RELEVANCE: Individuals carrying a higher polygenic burden for BIP and lower polygenic risk for MDD are more likely to benefit from lithium augmentation. Our findings suggest that disease-related PRS may aid in developing treatment prediction models for lithium augmentation response in depression, potentially informing clinical decision-making.
引用
- Kraft J, Buspavanich P, Braun A, et al. Polygenic Contributions to Lithium Augmentation Outcomes in Unipolar Depression. JAMA Psychiatry. 2025. PMID: 40900576. doi:10.1001/jamapsychiatry.2025.2039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。